Mass spectrometry-based targeted proteomics supports each step of drug development, from early discovery to preclinical phases and even clinical phases. Registrations are now open for a new webinar taking place on 29 January 2026, entitled ‘MS-based targeted proteomics: A cornerstone to progress drug development through preclinical and clinical phases‘. This webinar, hosted by DDW and supported by Evotec, will cover a diverse set of applications to illustrate how tailored and targeted proteomics fulfils scientific – and even regulatory – requirements at each step of drug development. It will also cover how to deal with low material inputs or low-abundant proteins. Whether you’re exploring biomarker options in early discovery or assessing drug candidates in preclinical or clinical stage, this webinar will equip you with actionable insights and real-world examples to accelerate your discovery efforts.
You will learn:
- How targeted proteomics supports different stages of drug development, including scientific and regulatory requirements
- More specifically, how fit-for-purpose targeted proteomics fulfils project specificities (sample preparation, LC/MS platforms and data analysis)
- Practical applications and case examples, such as working with low-input samples or detecting low-abundance proteins
About the Speaker:
Yvan Eb Levadoux, PhD, has over ten years of proteomics experience, specializing in targeted mass spectrometry workflows. He has developed FDA and ICH M10 compliant quantitative proteomics methods, including one validated as a primary endpoint in a Phase I clinical trial.
If the video has not loaded above, please click here.
